Research Paper Volume 15, Issue 24 pp 15025—15049
The efficacy of immune checkpoint inhibitors is limited in elderly NSCLC: a retrospective efficacy study and meta-analysis
Figure 3. Forest plots of overall survival of NSCLC patients < 75 years and ≥ 75 years by age. CI, confidence interval; ICIs, immune checkpoint inhibitors.